mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for PLA2G16
Gene summary
Basic gene Info.Gene symbolPLA2G16
Gene namephospholipase A2, group XVI
CytomapUCSC genome browser: 11q12.3
Type of geneprotein-coding
DescriptionCa-independent phospholipase A1/2H-rev 107 protein homologHRAS-like suppressor 1HRAS-like suppressor 3adipose-specific PLA2adipose-specific phospholipase A2group XVI phospholipase A1/A2group XVI phospholipase A2renal carcinoma antigen NY-REN-65
Modification date20141207
dbXrefs MIM : 613867
Ensembl : ENSG00000176485
HPRD : 13671
ProteinUniProt: P53816
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_PLA2G16
BioGPS: 11145
PathwayNCI Pathway Interaction Database: PLA2G16
Pathway Commons: PLA2G16
ContextiHOP: PLA2G16
ligand binding site mutation search in PubMed: PLA2G16
UCL Cancer Institute: PLA2G16
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0006644phospholipid metabolic process20100577

Ligand binding site mutations for PLA2G16

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for PLA2G16
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for PLA2G16 from PDB

Differential gene expression and gene-gene network for PLA2G16
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of PLA2G16 and the right PPI network was created from samples without mutations in the LBS of PLA2G16. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for PLA2G16
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for PLA2G16
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of PLA2G16 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of PLA2G16
Multiple alignments for P53816 in multiple species
LBSAA sequence# speciesSpecies
C113LTSENCEHFVN3Homo sapiens, Mus musculus, Rattus norvegicus
H23RPFYRHWAIYV1Homo sapiens
H23RPMYRHWAIYV1Mus musculus
H23RPMYSHWAIYV1Rattus norvegicus
L108EVLYRLTSENC2Mus musculus, Rattus norvegicus
L108EVLYKLTSENC1Homo sapiens
T109VLYRLTSENCE2Mus musculus, Rattus norvegicus
T109VLYKLTSENCE1Homo sapiens
W24PFYRHWAIYVG1Homo sapiens
W24PMYRHWAIYVG1Mus musculus
W24PMYSHWAIYVG1Rattus norvegicus
Y21IFRPFYRHWAI1Homo sapiens
Y21IFRPMYRHWAI1Mus musculus
Y21IFRPMYSHWAI1Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas